Effects of ezetimibe add-on to statin therapy on adipokine production in patients with metabolic syndrome and stable vascular disease

Journal of Cardiovascular Pharmacology

Volumn 56, Issue 3, 2010, Pages 241-245

  Gupta, Milan ^a,b,c   Szmitko, Paul E ^d   Tsigoulis, Michelle ^a   Braga, Manoela F B ^b   Kajil, Mahesh ^a   Herjikaka, Sheriar ^a   Quan, Adrian ^c   Teoh, Hwee ^a,c   Verma, Subodh ^a,c  

^a Canadian Cardiovascular Research Network   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

adipokines; adiponectin; cardiometabolic syndrome; ezetimibe

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EZETIMIBE; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MARKER; NICOTINIC ACID; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA;

ADD ON THERAPY; ADULT; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); DRUG EFFECT; FEMALE; HOMEOSTASIS; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; VASCULAR DISEASE;

ADIPOKINES; AGED; ANTICHOLESTEREMIC AGENTS; AZETIDINES; BIOLOGICAL MARKERS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; VASCULAR DISEASES;

EID: 77957560282     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181e7fd74     Document Type: Article

References (24)

1. Braunwald E. Shattuck lecture-cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med. 1997; 337:1360-1369.
2. Mokdad AH, Ford ES, Bowman B.A., et al Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003;289:76-79.
3. Lau DC, Dhillon B, Yan H., et al Adipokines: molecular links between obesity and atheroslcerosis. Am J Physiol Heart Circ Physiol. 2005;288: H2031-H2041.
4. Szmitko PE, Teoh H, Stewart D.J., et al Adiponectin and cardiovascular disease: state of the art? Am J Physiol Heart Circ Physiol. 2007;292: H1655-H1663.
5. Gagne C, Bays HE, Weiss S.R., et al; Ezetimibe Study Group. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol. 2002;90: 1084-1091.
6. Davidson MH, McGarry T, Bettis R., et al Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol. 2002;40:2125-2134.
7. Sager PT, Melani L, Lipka L., et al; Ezetimibe Study Group. Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein. Am J Cardiol. 2003;92:1414-1418.
8. Pearson TA, Ballantyne CM, Veltri E, et al Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy. Am J Cardiol. 2009;103:369-374.
9. Gouni-Berthold I., Berthold HK, Chamberland J.P., et al Short-term treatment with ezetimibe, simvastatin or their combination does not alter circulating adiponectin, resistin or leptin levels in healthy men. Clin Endocrinol (Oxf). 2008;68:536-541.
10. Deedwania P, Barter P, Carmena R., et al; Treating to New Targets Investigators. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet. 2006;368:919-928.
11. Tan CE, Ma S, Wai D., et al Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians? Diabetes Care. 2004;27:1182-1186.
12. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA. 1999;282: 2340-2346.
13. Ridker PM, Danielson E, Fonseca F.A., et al; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207.
14. Khan T, Hamilton MP, Mundy D.I., et al Impact of simvastatin on adipose tissue: pleiotropic effects in vivo. Endocrinology. 2009;150: 5262-5272.
15. Ando H, Sugimoto K, Yanagihara H., et al Effects of atorvastatin and pravastatin on glucose tolerance, adipokine levels and inflammatory markers in hypercholesterolaemic patients. Clin Exp Pharmacol Physiol. 2008;35:1012-1017.
16. Fleg JL, Mete M, Howard B.V., et al Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. J Am Coll Cardiol. 2008;52:2198-2205.
17. Kastelein JJ, Akdim F, Stroes E.S., et al; ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008;358:1431-1443.
18. Villines TC, Stanek EJ, Devine P.J., et al The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration. J Am Coll Cardiol. 2010; 55:2721-2726.
19. Ginsberg HN, Elam MB, Lovato L.C., et al Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563-1574.
20. Kater AL, Batista MC, Ferreira SR Improved endothelial function with simvastatin but unchanged insulin sensitivity with simvastatin or ezetimibe. Metabolism. 2010;59:921-926.
21. Assy N, Grozovski M, Bersudsky I., et al Effect of insulin-sensitizing agents in combination with ezetimibe, and valsartan in rats with non-alcoholic fatty liver disease. World J Gastroenterol. 2006;12: 4369-4376.
22. Nakagami H, Osako MK, Takami Y, et al Vascular protective effects of ezetimibe in ApoE-deficient mice. Atherosclerosis. 2009;203:51-58.
23. Kinlay S. Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein: a meta-analysis. J Am Coll Cardiol. 2007;49:2003-2009.
24. Ballantyne CM, Houri J, Notarbartolo A., et al; Ezetimibe Study Group. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation. 2003;107:2409-2415.